Navigation Links
AACR news: Studies show increasing evidence that androgen drives breast cancer
Date:4/10/2013

Estrogen and progesterone receptors, and the gene HER2 these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

"This is a continuing line of work with all evidence pointing toward the addition of the androgen receptor as potential target and useful marker in all of the major subtypes of breast cancer," says Jennifer Richer, PhD, investigator at the University of Colorado Cancer Center and co-director of the CU Cancer Center Tissue Processing and Procurement Core.

The finding of androgen receptors (AR) as a potential target in breast cancer is especially important in light of its prevalence in breast cancers that don't express other hormone receptor targets or have developed resistance to treatments that target estrogen dependence. Overall, approximately 77 percent of breast cancers are positive for AR, including 88 percent of cancers that are estrogen receptor positive, 59 percent of those that are HER2 positive, and 20-32 percent of triple negative breast cancers.

The study presented this week explores the ability of estrogen-positive (ER+) breast cancers to develop resistance to anti-estrogen drugs by potentially developing an alternative addiction to AR and hypothesizes that anti-androgen therapy, such as the drug enzalutamide (formerly MDV3100) as successful counters to breast cancers' evolution. First, Richer and colleagues used breast cancer tumor registries to discover that cancers with higher ratios of AR to ER protein had shorter time to relapse after anti-estrogen therapies. Cut off from their estrogen addition, these cancers may have turned to growth and survival via androgens instead.

The group then returned to the lab to explore the effects of anti-androgen therapies in cell lines and preclinical models.

"Remarkably, the anti-androgen drug enzalutamide had effects comparable to the anti-estrogen drug tamoxife
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. AACR news: New target plus new drug equals death of melanoma cells
7. AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
8. AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool
9. Studies reveal structure of EV71, a virus causing childhood illnesses
10. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
11. Autism Speaks awards $1.1 million to fund high priority studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Researchers at the University of Newcastle, England, ... the United States have revealed a large reservoir of ... analysis of blood samples from almost 3,000 infants born ... in 200 individuals in the general public harbor mitochondrial ...
... the International Primatological Society (IPS) Lifetime Achievement Award for ... was presented at the 12th Congress of the IPS ... also be given the Leakey Prize for revolutionizing our ... Foundation. He shares the prize with Jane Goodall. Nishida ...
... While the CDC recently reported that more moms than ever ... moms do not stick with it as long as they ... breastfeed, the new Brigham Young University study found that only ... short of the federal government,s goal to hit 50 percent ...
Cached Biology News:Large reservoir of mitochondrial DNA mutations identified in humans 2Springer editor Toshisada Nishida winner of 2 prestigious primatology awards 2New breastfeeding study shows most moms quit early 2
(Date:11/21/2014)... The November 2014 issue of BioTechniques ( ... journal featuring the following articles:, , ... in the retina , DNA from fingermarks ... chromogenic substrates in zebrafish , Re-use of ... , Nuclear LC3-positive puncta in stressed cells ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/18/2014)... November 17, 2014 RPS Diagnostics ... tests – today announces its third annual partnership ... (CDC) Get Smart About Antibiotics Week from November ... a national campaign designed to highlight the coordinated ... and non-profit and for-profit partners to provide education ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... Oct. 24 Favrille, Inc. (OTC,Bulletin Board: FVRL) announced ... for a reverse merger whereby Favrille would acquire,all of ... in a stock for stock merger that would result ... proposed transaction is,consummated on the terms set forth in ...
... five years after Jim Rider, the first American patient to receive ... patient milestone. , ... Bremen, Germany (PRWEB) October 24, ... worse, and the knowledge that many treatments are just not available ...
... p.m. EST, HOPKINTON, Mass., Oct. 23 ... conduct a conference call discussing the,company,s third quarter ... Monday,November 10. Kevin Hrusovsky, President and Chief Executive ... the call. Management will,discuss operational and financial results ...
Cached Biology Technology:Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction 2Stenum Hospital Does its 600th American Disc Replacement Surgery 2Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2
Request Info...
The BD OptEIA Rat TNF-alpha ELISA Kit is for the quantitative determination of TNF-alpha in rat serum, plasma and cell culture supernatant....
Request Info...
... Rat Antibody to Human CD66 acd ... expressed by human neutrophils and cells ... Clone YTH71.3 reacts with transfectants containing ... CEA subfamily members(2). ...
Biology Products: